Search
Results: 4
Changes in cannabis potency and first-time admissions to drug treatment
Tom P Freeman, Peggy van der Pol, Wil Kuijpers, Jeroen Wisselink, Ravi K Das, Sander Rigter, Margriet van Laar, Paul Griffiths, Wendy Swift, Raymond Niesink, Michael T Lynskey
Oct 31, 2018
Background The number of people entering specialist drug treatment for cannabis problems has increased considerably in recent years. The reasons for this are unclear, but rising cannabis potency could be a contributing...
Addiction Cannabis Drug Treatment Mental Health Potency Psychosis δ-9-tetrahydrocannabinol /dk/atira/pure/subjectarea/asjc/3200/3202 name=Applied Psychology /dk/atira/pure/subjectarea/asjc/2700/2738 name=Psychiatry and Mental health /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being name=SDG 3 - Good Health and Well-being
Changes in cannabis potency and first-time admissions to drug treatment
Tom P Freeman, Peggy van der Pol, Wil Kuijpers, Jeroen Wisselink, Ravi K Das, Sander Rigter, Margriet van Laar, Paul Griffiths, Wendy Swift, Raymond Niesink, Michael T Lynskey
Oct 31, 2018
Background The number of people entering specialist drug treatment for cannabis problems has increased considerably in recent years. The reasons for this are unclear, but rising cannabis potency could be a contributing...
Addiction Cannabis Drug Treatment Mental Health Potency Psychosis δ-9-tetrahydrocannabinol /dk/atira/pure/subjectarea/asjc/3200/3202 name=Applied Psychology /dk/atira/pure/subjectarea/asjc/2700/2738 name=Psychiatry and Mental health /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being name=SDG 3 - Good Health and Well-being
Prevention And Treatment of Hypertension With Algorithm-based therapy (PATHWAY) number 2
Bryan Williams, Thomas M MacDonald, Mark Caulfield, J Kennedy Cruickshank, Gordon McInnes, Peter Sever, David J Webb, Jackie Salsbury, Steve Morant, Ian Ford, Morris J Brown
Sep 02, 2015
Drug Treatment Resistant hypertension Adolescent Adult Aged Algorithms Angiotensin Receptor Antagonists Angiotensin-Converting Enzyme Inhibitors Antihypertensive Agents Calcium Channel Blockers Clinical Protocols Cross-Over Studies Diuretics Double-Blind Method Drug Therapy Combination Humans Hypertension Male Middle Aged Spironolactone Young Adult
Are patients in heart failure trials representative of primary care populations? A systematic review.
Nicholas D Gollop, John Ford, Pieter Mackeith, Caroline Thurlow, Rachel Wakelin, Nicholas Steel, Robert Fleetcroft
Mar 02, 2020
BACKGROUND: Guidelines recommend drug treatment for patients with heart failure with a reduced ejection fraction (HFrEF), however the evidence for benefit in patients with mild disease, such as most in primary care, is...